A Study of MKC-442 in Combination With Other Anti-HIV Drugs
Phase 2
Completed
- Conditions
- HIV Infections
- Registration Number
- NCT00002412
- Lead Sponsor
- Triangle Pharmaceuticals
- Brief Summary
The purpose of this study is to see if it is safe and effective to give MKC-442 plus stavudine (d4T) plus didanosine (ddI) plus hydroxyurea.
- Detailed Description
Patients are randomized to receive either MKC-442 or placebo, along with stavudine(d4T), didanosine(ddI), and hydroxyurea. Patients will be treated and followed for 48 weeks.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does MKC-442 target in HIV-infected patients with protease inhibitor experience?
How does MKC-442 combination therapy compare to standard-of-care regimens for HIV-1 treatment in clinical trials?
Which biomarkers correlate with virologic response to MKC-442 plus d4T/ddI/hydroxyurea in HIV-1 infected individuals?
What adverse event profiles are associated with MKC-442 when combined with stavudine, didanosine, and hydroxyurea?
Are there alternative nucleoside reverse transcriptase inhibitor combinations to MKC-442 for HIV treatment-experienced patients?
Trial Locations
- Locations (1)
Dr Robert Wallace
🇺🇸St. Petersburg, Florida, United States
Dr Robert Wallace🇺🇸St. Petersburg, Florida, United States